Skip to main content

Table 6 Risk of fracture associated with different types of ADT

From: Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand

 

Adjusted OR (95 % CI) any fracturea

Adjusted OR (95 % CI) accidental fracturea

Adjusted OR (95 % CI) hip fracturea

No ADT

1.0 (Reference)

1.0 (Reference)

1.0 (Reference)

GnRH agonists + anti-androgens

3.48 (3.07–3.96)

1.60 (1.36–1.88)

1.82 (1.39–2.38)

GnRH agonist only

1.33 (1.09–1.63)

1.17 (0.93–1.47)

1.70 (1.19–2.42)

Anti-androgen only

2.11 (1.72–2.59)

1.37 (1.07–1.77)

1.81 (1.24–2.63)

Orchiectomy alone

2.54 (1.76–3.66)

2.18 (1.43–3.33)

1.88 (0.96–3.67)

Orchiectomy + pharmacologic ADT

4.32 (3.34–5.58)

1.39 (0.93–2.07)

1.59 (0.86–2.93)

  1. ADT androgen deprivation therapy, GnRH gonadotropin-releasing hormone, OR odds ratio, CI confidence interval
  2. aAdjusted for age at diagnosis and ethnicity
  3. Bold indicate significant p-value (<0.5)